Literature DB >> 20577781

Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.

A Girolami1, N Candeo, G Berti De Marinis, E Bonamigo, B Girolami.   

Abstract

Thrombotic manifestations occurring in patients with coagulation defects have drawn considerable attention during the last decade. It concerned mainly patients with hemophilia, vW disease or FVII deficiency. Occasional reports involved also the deficiencies of the contact phase of blood coagulation, mainly FXII deficiency. The purpose of the present study was to evaluate the comparative incidence of thrombosis in all reported patients with FXII, Prekallikrein and Kininogens deficiencies. Out of the reported 341 cases with these conditions that could be tracked there were 43 cases with thrombosis. More specifically, there were 32 patients with FXII deficiency who also had a thrombotic event (16 arterial and 16 venous). As far as Prekallikrein deficiency is concerned, there were nine cases with thrombosis (five arterial and four venous). Finally, two patients with Total or High molecular weight Kininogen deficiencies had also a thrombotic manifestation (one arterial and one venous). The thrombotic manifestations were M.I. 11 cases; ischemic stroke 9 cases; peripheral arteries 3 cases; deep vein thrombosis with or without pulmonary embolism 17 cases; thrombosis in other veins 3 cases. Congenital or acquired associated prothrombotic risk factors were present in 33 out of 36 cases. In three cases the existence of associated risk factors was excluded whereas in the remaining seven patients no mention is made in this regard. This study clearly indicates that the severe in vitro coagulation defect seen in these conditions does not protect from thrombosis.

Entities:  

Mesh:

Year:  2011        PMID: 20577781     DOI: 10.1007/s11239-010-0495-z

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  44 in total

1.  Combined severe factor XII deficiency and homozygous factor V Leiden mutation in a patient with venous thrombosis.

Authors:  P Miljic; M Colovic; D Boskovic; Lj Rakicevic; V Djordjevic
Journal:  Thromb Res       Date:  2002-05-15       Impact factor: 3.944

Review 2.  Intrinsic pathway of coagulation and arterial thrombosis.

Authors:  David Gailani; Thomas Renné
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-04       Impact factor: 8.311

3.  A renaissance for the contact system in blood coagulation?

Authors:  Yuval Blat; Dietmar Seiffert
Journal:  Thromb Haemost       Date:  2008-03       Impact factor: 5.249

4.  Lemierre's syndrome complicating bacterial pharyngitis in a patient with undiagnosed factor XII deficiency.

Authors:  Veronica Hlibczuk
Journal:  J Emerg Med       Date:  2007-04-16       Impact factor: 1.484

5.  Fletcher factor deficiency and myocardial infarction.

Authors:  Z Currimbhoy; V Vinciguerra; P Palakavongs; P Kuslansky; T J Degnan
Journal:  Am J Clin Pathol       Date:  1976-06       Impact factor: 2.493

6.  Symptomatic combined homozygous factor XII deficiency and heterozygous factor V Leiden. luscaber@tin.it.

Authors:  A Girolami; P Simioni; L Scarano; B Girolami; P Zerbinati
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

7.  Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.

Authors:  R W Colman; A Bagdasarian; R C Talamo; C F Scott; M Seavey; J A Guimaraes; J V Pierce; A P Kaplan
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

Review 8.  Thrombotic complications in patients with hereditary bleeding disorders.

Authors:  Massimo Franchini
Journal:  Thromb Haemost       Date:  2004-08       Impact factor: 5.249

Review 9.  The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature.

Authors:  A Girolami; M L Randi; S Gavasso; A M Lombardi; F Spiezia
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

10.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

View more
  6 in total

1.  Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period.

Authors:  Antonio Girolami; Silvia Ferrari; Elisabetta Cosi; Bruno Girolami; Maria Luigia Randi
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

2.  Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

Authors:  Alexey S Revenko; Dacao Gao; Jeff R Crosby; Gourab Bhattacharjee; Chenguang Zhao; Chris May; David Gailani; Brett P Monia; A Robert MacLeod
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

3.  Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates.

Authors:  Jeffrey R Crosby; Ulla Marzec; Alexey S Revenko; Chenguang Zhao; Dacao Gao; Anton Matafonov; David Gailani; A Robert MacLeod; Erik I Tucker; Andras Gruber; Stephen R Hanson; Brett P Monia
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-04       Impact factor: 8.311

Review 4.  The Effects of the Contact Activation System on Hemorrhage.

Authors:  Fabrício Simão; Edward P Feener
Journal:  Front Med (Lausanne)       Date:  2017-07-31

5.  Prekallikrein deficiency presenting as recurrent cerebrovascular accident: case report and review of the literature.

Authors:  Esteban Uribe Bojanini; Arturo Loaiza-Bonilla; Agustin Pimentel
Journal:  Case Rep Hematol       Date:  2012-08-16

6.  Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI.

Authors:  Katherine J Kearney; Juliet Butler; Olga M Posada; Clare Wilson; Samantha Heal; Majid Ali; Lewis Hardy; Josefin Ahnström; David Gailani; Richard Foster; Emma Hethershaw; Colin Longstaff; Helen Philippou
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.